30 August 2016
: Case report
DRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy
Daisuke MiyazuABDEF, Nobuhiro KodamaABD, Daiki YamashitaB, Hirokazu TanakaB, Sachiko InoueB, Osamu ImakyureBD, Masaaki HirakawaAD, Hideki ShutoABDEF, Yasufumi KataokaAEGDOI: 10.12659/AJCR.899149
Am J Case Rep 2016; 17:625-631
Abstract
BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening syndrome comprising severe skin eruption, fever, eosinophilia, lymphadenopathy, and involvement of internal organs. Here, we describe a case of DRESS syndrome caused by cross-reactivity between vancomycin and subsequent teicoplanin administration.
CASE REPORT: A 79-year-old male was admitted to our hospital for the treatment of injuries incurred in a traffic accident. Eosinophilia and lung dysfunction appeared after vancomycin administration. These symptoms were improved temporarily by withdrawal of vancomycin and administration of corticosteroid, but exacerbated by subsequent teicoplanin administration. These symptoms disappeared after discontinuation of teicoplanin. Based on comprehensive assessment of the overall clinical course, we judged that DRESS syndrome was induced by cross-reactivity between vancomycin and subsequent teicoplanin administration. Using the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring system, we categorized DRESS syndrome related to vancomycin and teicoplanin as “probable.” We describe, for the first time, DRESS syndrome (defined using the RegiSCAR scoring system) caused by cross-reactivity between vancomycin and subsequent teicoplanin administration.
CONCLUSIONS: Clinicians should be aware that DRESS syndrome can be induced by cross-reactivity between vancomycin and teicoplanin.
Keywords: Drug Hypersensitivity Syndrome, Lung Diseases, Interstitial, Teicoplanin, Vancomycin
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946911
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947730
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946625
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946795
Most Viewed Current Articles
21 Jun 2024 : Case report
98,661
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
53,011
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
33,935
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
23,965
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200